Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qimai Tongguan
- Development stage
- Preclinical
- Lead developer
- Guangzhou University of Chinese Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Qimai Tongguan (芪麦通冠颗粒) is a traditional Chinese medicine granule formulation used primarily for the treatment of heart failure following acute myocardial infarction. It is based on a specific prescription formula (协定方) and has been studied in clinical trials for its effects on cardiac function and ventricular remodeling post-myocardial infarction[1][6]. The mechanism of action is not fully elucidated but likely involves multi-targeted effects typical of traditional Chinese herbal medicines, such as improving cardiac function and reducing adverse remodeling.
- Brand names
- 芪麦通冠颗粒Qimai Tongguan
- Other names
- 芪麦通冠协定方新通冠颗粒
Beyond the preview
Go deeper on Qimai Tongguan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qimai Tongguan.